Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 2 selected

Type

Guidance programme

Showing 1 to 10 of 16

TitleReference numberPublishedLast updated
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and overTA1044
Advanced breast cancer: diagnosis and treatmentCG81
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and overTA1033
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and overTA1038
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and overTA1039
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapyTA1040
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTE12

Results per page

  1. 10
  2. 25
  3. 50
  4. All